Mohamed Elrefaei
Overview
Explore the profile of Mohamed Elrefaei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah S, Du Z, El Jack K, Pham S, Elrefaei M
Transpl Immunol
. 2024 Dec;
88:102161.
PMID: 39645000
The Purpose: The COVID-19 pandemic has led to significant morbidity and mortality in lung transplant recipients (LTR). Respiratory viral infections may be associated with de-novo HLA donor-specific antibody (DSA) production...
2.
Sayed A, Elrefaei M, Awad K, Salah H, Mandrola J, Foy A
JAMA Netw Open
. 2024 Nov;
7(11):e2446684.
PMID: 39602122
Importance: Heart failure (HF) hospitalization is a common end point in HF trials; however, how HF hospitalization is associated with all-cause hospitalization in terms of proportionality, correlation of treatment effects,...
3.
Induction immunosuppression strategies and outcomes post-lung transplant: A single center experience
Narula T, Alvarez F, Abdelmoneim Y, Erasmus D, Li Z, Elrefaei M
Transpl Immunol
. 2024 Jul;
85:102081.
PMID: 38986916
Purpose: Currently 80% of lung transplant centers use induction immunosuppression. However, there is a lack of standardization of induction protocols within and across lung transplant centers. This study explores the...
4.
Brow D, Shike H, Kendrick J, Pettersson L, Mineishi S, Claxton D, et al.
Hum Immunol
. 2024 Mar;
85(3):110794.
PMID: 38553384
Chimerism analysis is used to evaluate patients after allogeneic hematopoietic stem cell transplant (allo-HSCT) for engraftment and minimal measurable residual disease (MRD) monitoring. A combination of short-tandem repeat (STR) and...
5.
Du Z, Murrin M, Patel P, Williams C, Elrefaei M
HLA
. 2024 Mar;
103(3):e15443.
PMID: 38488750
HLA-DQA1*05:101 differs from HLA-DQA1*05:01:01:02 by one nucleotide substitution at codon 221 (CGT>TGT) in exon 4.
6.
Xu Q, Elrefaei M, Taupin J, Hitchman K, Hiho S, Gareau A, et al.
J Heart Lung Transplant
. 2023 Dec;
43(4):663-672.
PMID: 38141896
Background: Chronic lung allograft dysfunction (CLAD) is the major cause of adverse outcomes in lung transplant recipients. Multiple factors, such as infection, alloimmunity, and autoimmunity, may lead to CLAD. Here,...
7.
Du Z, Williams C, Robinson T, Hardage B, Elrefaei M
HLA
. 2023 Dec;
103(1):e15324.
PMID: 38081589
HLA-C*03:648 differs from HLA-C*03:04:02 by one nucleotide substitution at Codon -23 (CGG > CTG) in exon 1.
8.
Du Z, Williams C, Santiago R, Ussery T, Elrefaei M
HLA
. 2023 Dec;
103(1):e15327.
PMID: 38073446
HLA-B*57:168 differs from HLA-B*57:01:01:01 by one nucleotide substitution at codon 325 (TGC > TCC) in exon 7.
9.
Ibrahim I, Ali O, El-Sahar A, Elrefaei M, El-Sheikh N
J Clin Exp Hepatol
. 2023 Nov;
13(6):1008-1016.
PMID: 37975051
Background: Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. Aim: This study aimed to assess serum human telomerase enzyme (hTERT) levels and their relation to...
10.
Hanouneh T, Attieh R, Craver E, Jebrini A, Elrefaei M, Jarmi T
Transpl Immunol
. 2023 Nov;
81:101958.
PMID: 37949378
Purpose: Blood group B kidney transplant candidates have lower transplantation rates and longer waiting times compared to other blood groups. Kidney transplantation from blood group A2-to-B has offered a solution...